MELBOURNE, Australia, Nov. 17 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited today announced the appointment of Mr. Richard Hazleton, the former chairman of the US-based global corporation Dow Corning, as a Non-Executive Director.
Mr. Hazleton began his Dow Corning career in 1965. He held numerous positions in engineering, manufacturing and finance, both in the US and Europe, before becoming Chief Executive Officer of the company in 1993, and Chairman of the Board of Directors and CEO in 1994. He retired from Dow Corning in 2001. Mr. Hazelton also held the position of Chairman of Dendritic Nanotechnologies Inc (DNT) from 2004 and until Starpharma's acquisition of the company in October 2006.
"The appointment of Mr. Hazleton is of major significance to Starpharma and will assist in our rapid expansion to the United States following our acquisition of DNT. His experience and contacts in international business will be a major asset to Starpharma and complement the skills and experience of our current Board," said CEO Dr. Jackie Fairley.
The Chairman of Starpharma, Mr. Peter Bartels added: "This is a major coup for Starpharma and we welcome wholeheartedly Dick to our Board. He joins at an ideal time for the company, when we are increasingly focused on expanding our profile and business in the United States to fully appreciate the value of our now expanded portfolio of dendrimer-based pharmaceutical and industrial products."
Mr. Hazleton has served on the Boards of the American Chemistry Council and the Chemical Bank and Trust Company (Midland, MI, USA) as well as several non-profit social service agencies in Michigan and Belgium.
The appointment is effective from 1 December 2006.
Starpharma Holdings Limited is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(TM) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
In the pharmaceutical field Starpharma has additional specific programs in the areas of Drug Delivery and ADME Engineering(TM) (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signaling and targeting groups are added to allow location of specific cell type, such as cancer cells).
More broadly the company is actively exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.
SPL has a comprehensive IP portfolio that comprises more than 180 patents/applications issued and pending across 32 patent families -- a unique level of IP concentration among nanotechnology companies.
American Depositary Receipts (ADRs): Starpharma's ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.
For further information:
Tel: +61 2 9237 2800
Mob: +61 422 916 422
Dr. Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
+61 3 8532 2702
CONTACT: Media: Rebecca Piercy of Buchan Consulting for Starpharma,+61-2-9237-2800, Mob: +61-422-916-422, email@example.com; Dr. JackieFairley, Chief Executive Officer, +61-3-8532-2704, or Ben Rogers, CompanySecretary, +61-3-8532-2702, firstname.lastname@example.org, both of Starpharma